Growing clinical and research interest in Lp(a) as an independent risk factor for a spectrum of cardiovascular diseases was reflected in a broad range of presentations focused on Lp(a) at ACC.24 Scientific Sessions (6-8 April 2024, Atlanta, USA and online). These included fresh insights into the role of Lp(a) in patients with coronary artery disease […]
Real world analyses of patients with coronary artery disease (CAD) or heart failure (HF) have highlighted Lp(a) as an independent risk factor for adverse cardiovascular (CV) outcomes.1,2
Lp(a) measurement in clinical practice is infrequent even among patients with atherosclerotic cardiovascular disease (ASCVD), though there are signs that testing is becoming more common and that it can lead to increased use of lipid lowering therapies (LLT), according to results of two large US studies.1,2
High concordance rates at multiple Lp(a) thresholds have been reported for mass units (mg/dl) and molar units (nmol/L) of Lp(a) using the Denka Seiken assay, generally considered to be an assay which is less sensitive to apo(a) isoforms.
Elevated Lp(a) may help to explain why people with HIV are predisposed to impaired coronary endothelial function (CEF) and increased cardiovascular risk.
A retrospective review of heart transplant recipients has indicated the possible involvement of Lp(a) in the development of cardiac allograft vasculopathy (CAV) – a major cause of morbidity and mortality after heart transplantation.
